Corvus Pharmaceuticals (NASDAQ: CRVS – Get a rating) and Pharmaxis (OTCMKTS:PXSLY – Get a rating) are both small-cap medical companies, but which business is superior? We’ll compare the two companies based on earnings strength, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Analyst Recommendations
This is a summary of the current recommendations for Corvus Pharmaceuticals and Pharmaxis, as provided by MarketBeat.com.
| Sales Ratings | Hold odds | Buy reviews | Strong buy odds | Rating | |
| Corvus Pharmaceuticals | 0 | 1 | 3 | 0 | 2.75 |
| Pharmaxis | 0 | 0 | 0 | 0 | N / A |
Corvus Pharmaceuticals currently has a consensus price target of $6.38, indicating a potential upside of 358.63%. Given Corvus Pharmaceuticals’ possible higher upside, stock analysts clearly believe that Corvus Pharmaceuticals is more favorable than Pharmaxis.
Risk and Volatility
Corvus Pharmaceuticals has a beta of 1, indicating that its stock price has a volatility profile similar to that of the S&P 500. Comparatively, Pharmaxis has a beta of 1.22, indicating that its stock price is 22% higher. volatile than the S&P 500.
Profitability
This table compares the net margins, return on equity and return on assets of Corvus Pharmaceuticals and Pharmaxis.
| Net margins | Return on equity | return on assets | |
| Corvus Pharmaceuticals | N / A | -44.00% | -38.66% |
| Pharmaxis | N / A | N / A | N / A |
Benefits and evaluation
This table compares the revenue, earnings per share and valuation of Corvus Pharmaceuticals and Pharmaxis.
| Gross revenue | Price/sales ratio | Net revenue | Earnings per share | Price/earnings ratio | |
| Corvus Pharmaceuticals | N / A | N / A | -$43.24 million | ($1.06) | -1.31 |
| Pharmaxis | $8.75 million | 3.03 | -9.36 million dollars | N / A | N / A |
Pharmaxis has higher revenue and profit than Corvus Pharmaceuticals.
Insider and Institutional Ownership
77.9% of Corvus Pharmaceuticals shares are held by institutional investors. 45.1% of the shares of Corvus Pharmaceuticals are held by insiders of the company. Strong institutional ownership indicates that large money managers, endowments, and hedge funds believe a company will outperform the market over the long term.
Summary
Pharmaxis beats Corvus Pharmaceuticals on 5 out of 9 factors compared between the two stocks.
About Corvus Pharmaceuticals (Get a rating)
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of immuno-oncology therapies. Its lead product candidate is mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in a Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company is also developing CPI-818, a covalent ITK inhibitor, which is in a Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells. ; and Ciforadenant (CPI-444), an oral small molecule A2A receptor antagonist that is in a Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical-stage products include CPI-182, an antibody designed to block myeloid inflammation and suppression; and CPI-935, an A2B adenosine receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development of its pipeline of targeted investigational drugs. The company was incorporated in 2014 and is based in Burlingame, California.
About Pharmaxis (Get a rating)
Pharmaxis Ltd engages in the research, development and marketing of health products for the treatment of fibrotic and inflammatory diseases worldwide. The Company operates through two segments, the Mannitol business and the development of new drugs. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airway inflammation test used to identify nervous or overreactive airways, as well as to aid in the diagnosis and management of asthma. The Company’s product portfolio includes amine oxidase inhibitors including semicarbazide responsive amine oxidase for diabetic retinopathy; selective lysyl oxidase inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, renal fibrosis and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, including cancers and scars. She is also developing Orbital, a dry powder inhaler to deliver large doses of medicine to the lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Get news and reviews for Corvus Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com’s free daily email newsletter.
